Immune control in colorectal cancer : A study done on the treatment of cancer has given some good signs. A recent research has found out why immune checkpoint resistance does not work in some types of colorectal cancer and what can be a strategy to deal with such resistances. ? According to the news report published in Dainik Jagran newspaper, the immune checkpoint has revolutionized the immune response against tumor cells in the treatment of cancer. Whereas in many patients, especially those with colorectal (intestine and rectal) cancer, the drug does not have an adequate effect. This study, led by researchers from MGS (Massachusetts General Hospital) and University of Geneva (UNIGE), was published in the journal PNAS. published happened.
It is further written in this report that the director of EL Steel Laboratories for Tumor Biology of MGH and the author of this research, Dr. Rakesh K Jain And Andrew Work Cook, Professor of Radiation Oncology at Harvard Medical School, said that liver metastasis is a major cause of death for colorectal cancer victims. Meaning the cancer has spread to the liver.
what was the result
co-writer of this research Dai Fukumura It is said that we found that in the case of colorectal cancer in the mice model study, the immune checkpoint inhibitors behaved similarly to the patients. The results revealed how the environment in which cancer cells grow could affect the effectiveness of immunotherapy. Also, the most important indication was that this model can be used in the study of working resistance of immune checkpoints, because more or less the same situation occurs in patients with colorectal cancer.
To investigate how liver metastasis responds to immune checkpoint blocking, Jain and co-workers injected a structure of immune cells into the skin of mice liver metastases. compared to colorectal cancer cells. It found that liver metastases lacked certain immune cells, called dendritic cells, and were important in activating other immune cells (cytotoxic T lymphocytes). These cytotoxic T lymphocytes can kill cancer cells. The same situation was observed in liver metastases of patients that lacked denditic cells and activated T lymphocytes.
When researchers increased the number of denditic cells through a specific process in liver metastasis, they found an increase in cytotoxic T lymphocytes in the tumor and the tumor became more sensitive to immune checkpoint inhibitors.
Used to understand discrepancy
Dr Rakesh Jain says that when colorectal cancer spreads to the liver, in most such cases the immune checkpoint resistance response is no longer effective. But when the research team injected colorectal cancer cells into the skin of the back of the mice, the immune checkpoint response was good, whereas this is not seen in the patients. Researchers injected cancer cells into the intestine and liver to understand this discrepancy.